Modality
Fusion Protein
MOA
DLL3 ADC
Target
TROP-2
Pathway
Angiogenesis
LNWM
Development Pipeline
Preclinical
Oct 2024
→ Jan 2025
PreclinicalCurrent
NCT07561614
2,543 pts·WM
2024-10→2025-01·Terminated
2,543 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-061.2y agoInterim· WM
Trial Timeline
Q42025
Preclinical
Termina…
Catalysts
Interim
2025-01-06 · 1.2y ago
WM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07561614 | Preclinical | WM | Terminated | 2543 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 | |
| GPC-2382 | Structure Ther | Preclinical | TROP-2 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| GLP-3342 | Galapagos | Phase 1/2 | PLK4 |